Exosome therapy for mild to moderate Alzheimer's disease
Part of Brain & nervous system clinical trials.
This trial tests a new drug made from stem cell exosomes (CB-Exo-A600) to see if it can help people with mild to moderate Alzheimer's disease. It aims to slow down symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 50 years or older.
- Have mild to moderate Alzheimer's disease (with a diagnosis confirmed by spinal fluid, PET scan, or blood test within the last 3 years).
- Have a recent MRI or CT scan showing changes consistent with Alzheimer's and no other major brain problems.
- Score between 10 and 24 on a memory and thinking test (MMSE).
- Have a reliable caregiver who lives with you or helps you at least 2 hours a day, 3 days a week.
- Be on stable doses of Alzheimer's medications (like donepezil or memantine) for at least 60 days before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a nasal drop made from tiny cell particles (extracellular vesicles) for ALS. The goal is to see if it's safe and if it can slow down the disease. It may be an option if your ALS is in the early to moderate stage.
This trial tests a nasal drop made from stem cell components. It may act directly in the brain to help slow or treat several conditions like Alzheimer's, Parkinson's, multiple system atrophy, dementia with Lewy bodies, or frontotemporal dementia.
This study tests a new treatment using tiny particles from stem cells (called exosomes) given as a nasal spray. It aims to see if it can help people with early-onset Alzheimer's disease, which starts before age 65.
This trial tests a new treatment using tiny particles from stem cells (exosomes) given through an IV. It aims to slow down or improve symptoms of frontotemporal dementia, a type of dementia that affects behavior and language.
This trial tests a stem cell treatment for people with early-stage Alzheimer's disease. It aims to see if the treatment can help slow memory loss or other symptoms. You must have a specific blood test showing inflammation in the body to qualify.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
Hear when a new Mild to Moderate Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.